このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Atea Pharmaceuticals マネジメント

マネジメント基準チェック /24

Atea Pharmaceuticals'の CEO はJean-Pierre Sommadossiで、 Jul2012年に任命され、の在任期間は 11.92年です。の年間総報酬は$ 5.93Mで、 11.5%給与と88.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の7.17%を直接所有しており、その価値は$ 21.08M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と4.8年です。

主要情報

Jean-Pierre Sommadossi

最高経営責任者

US$5.9m

報酬総額

CEO給与比率	11.5%
CEO在任期間	11.9yrs
CEOの所有権	7.2%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30

CEO報酬分析

Atea Pharmaceuticals の収益と比較して、Jean-Pierre Sommadossi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$164m
Dec 31 2023	US$6m	US$683k	-US$136m
Sep 30 2023	n/a	n/a	-US$131m
Jun 30 2023	n/a	n/a	-US$106m
Mar 31 2023	n/a	n/a	-US$109m
Dec 31 2022	US$6m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	US$36m
Jun 30 2022	n/a	n/a	US$16m
Mar 31 2022	n/a	n/a	US$48m
Dec 31 2021	US$34m	US$650k	US$121m
Sep 30 2021	n/a	n/a	US$25m
Jun 30 2021	n/a	n/a	US$35m
Mar 31 2021	n/a	n/a	US$24m
Dec 31 2020	US$3m	US$437k	-US$11m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$811k	US$400k	-US$14m

報酬と市場: Jean-Pierreの総報酬 ($USD 5.93M ) は、 US市場 ($USD 1.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Jean-Pierreの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jean-Pierre Sommadossi (68 yo)

11.9yrs

在職期間

US$5,925,790

報酬

Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jean-Pierre Sommadossi	Founder	11.9yrs	US$5.93m	7.17% $ 20.4m
Andrea Corcoran	CFO, Executive VP of Legal & Secretary	10.5yrs	US$1.96m	0.80% $ 2.3m
Wayne Foster	Executive VP of Finance & Chief Accounting Officer	2.4yrs	US$1.52m	0.025% $ 70.5k
Janet M. J. Hammond	Chief Development Officer	3.8yrs	US$2.11m	0.042% $ 119.5k
Maria Horga	Chief Medical Officer	3.8yrs	US$1.85m	0.030% $ 86.7k
Jonae Barnes	Senior Vice President of Investor Relations & Corporate Communications	3.4yrs	データなし	データなし
Ariyapadi Krishnaraj	Vice President of Marketing	2.4yrs	データなし	データなし
Adel Moussa	Executive Vice President of Chemistry	no data	データなし	データなし
Xiao-Jian Zhou	Executive Vice President of Early Stage Development	no data	データなし	データなし
John Vavricka	Chief Commercial Officer	5.7yrs	US$1.52m	0.12% $ 351.6k
Keith Pietropaolo	Executive VP of Clinical Sciences & Project Management	4.4yrs	データなし	データなし
Jayanthi Wolf	Executive Vice President of Regulatory Affairs	3.4yrs	データなし	データなし

3.8yrs

平均在職期間

61.5yo

平均年齢

経験豊富な経営陣: AVIRの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jean-Pierre Sommadossi	Founder	11.9yrs	US$5.93m	7.17% $ 20.4m
Barbara Duncan	Independent Director	3.7yrs	US$332.10k	0.039% $ 112.0k
Bruno Lucidi	Independent Director	9.8yrs	US$324.60k	0.099% $ 281.1k
Franklin Berger	Lead Independent Director	4.8yrs	US$357.10k	0.96% $ 2.7m
Bruce Polsky	Independent Director	9.6yrs	US$324.60k	0.078% $ 221.8k
Polly Murphy	Independent Director	3.8yrs	US$327.10k	0.067% $ 190.8k
Jerome Adams	Independent Director	3.1yrs	US$442.10k	0.039% $ 112.0k

4.8yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: AVIRの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Atea Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Independent Director recently sold US$61k worth of stock

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Founder notifies of intention to sell stock

Insufficient new directors

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Recent updates

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Founder notifies of intention to sell stock

Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19

Price target decreased by 15% to US$5.33

Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR).

Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR) for approximately $480 million.

Investor sentiment deteriorates as stock falls 16%

Price target decreased to US$9.00

Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea wins FDA Fast Track status for dengue treatment

Investor sentiment deteriorated over the past week

Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Consensus forecasts updated

First half 2022 earnings released

Atea Pharmaceuticals Q2 2022 Earnings Preview

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Growth Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$10.50

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$11.67

Atea Pharmaceuticals, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

Price target decreased to US$15.50

Consensus EPS estimates increase by 131%

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Independent Director recently bought US$103k worth of stock

Consensus forecasts updated

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in Covid-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Investor sentiment deteriorated over the past week

Price target decreased to US$16.25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Consensus EPS estimates increase to US$0.62

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc. Announces Positive Interim Results from the Global Phase 2 Study Evaluating AT-527

Independent Director Andrew A. Hack has left the company

Independent Director Andrew A. Hack has left the company

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$1.70b

Investor sentiment improved over the past week

Consensus forecasts updated

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

マネジメント基準チェック /24